期刊
LEUKEMIA
卷 28, 期 4, 页码 804-812出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2013.281
关键词
miRNA; AML; miR-135a; miR-196b; miR-409-3p; miR-644
资金
- Sociedad Espanola de Hematologia y Hemoterapia
- Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III [N-2004-FS041085, PI080158, FIS-PI0900547, PI1100872, RETICS RD06/0020/0004, RD12/0036/0010, RD12/0036/0071]
- SDCSD from School of Medicine
- Fundacion Espanola de Hematologia y Hemoterapia
Acute myeloid leukemia (AML) is a heterogeneous disease, and optimal treatment varies according to cytogenetic risk factors and molecular markers. Several studies have demonstrated the prognostic importance of microRNAs (miRNAs) in AML. Here we report a potential association between miRNA expression and clinical outcome in 238 intermediate-risk cytogenetic AML (IR-AML) patients from 16 institutions in the CETLAM cooperative group. We first profiled 670 miRNAs in a subset of 85 IR-AML patients from a single institution and identified 10 outcome-related miRNAs. We then validated these 10 miRNAs by individual assays in the total cohort and confirmed the prognostic impact of 4 miRNAs. High levels of miR-196b and miR-644 were independently associated with shorter overall survival, and low levels of miR-135a and miR-409-3p with a higher risk of relapse. Interestingly, miR-135a and miR-409-3p maintained their independent prognostic value within the unfavorable molecular subcategory (wild-type NPM1 and CEBPA and/or FLT3-ITD), and miR-644 retained its value within the favorable molecular subcategory. miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据